Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H23ClN2 |
Molecular Weight | 314.853 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCCN1c2ccccc2CCc3ccc(cc31)Cl
InChI
InChIKey=GDLIGKIOYRNHDA-UHFFFAOYSA-N
InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
Molecular Formula | C19H23ClN2 |
Molecular Weight | 314.853 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0051610 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ANAFRANIL Approved UseClomipramine hydrochloride capsules USP are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). Launch Date6.3089279E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
31.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8991493 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOMIPRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
92 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOMIPRAMINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
736 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8991493 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOMIPRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8991493 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOMIPRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Other AEs: Dry mouth, Constipation... Other AEs: Dry mouth (42.9%) Sources: Constipation (25%) Somnolence (24.1%) Tremor (22.3%) Dizziness (17.9%) Nausea (16.1%) Sweating (13.4%) Asthenia (9.8%) Insomnia (8%) Abdominal pain (3.6%) |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Other AEs: Somnolence, Tremor... Other AEs: Somnolence (46%) Sources: Tremor (33%) Dizziness (41%) Headache (28%) Insomnia (11%) Nervousness (4%) Myoclonus (2%) Paresthesia (2%) Memory impairment (7%) Anxiety (2%) Twitching (4%) Hypertonia (2%) Sleep disorder (9%) Confusion (2%) Depersonalization (2%) Irritability (2%) Panic reaction (2%) Aggressive reaction (2%) Paresis (2%) Sweating increased (9%) Rash (4%) Pruritus (2%) Skin odor abnormal (2%) Dry mouth (63%) Constipation (22%) Nausea (9%) Dyspepsia (13%) Diarrhea (7%) Anorexia (22%) Abdominal pain (13%) Vomiting (7%) Eructation (2%) Ulcerative stomatitis (2%) Fatigue (35%) Weight increase (2%) Flushing (7%) Hot flushes (2%) Chest pain (7%) Fever (2%) Allergy (7%) Pain (4%) Weight decrease (7%) Otitis media (4%) Asthenia (2%) Halitosis (2%) Postural hypotension (4%) Palpitation (4%) Tachycardia (2%) Syncope (2%) Rhinitis (7%) Sinusitis (2%) Coughing (4%) Bronchospasm (7%) Dyspnea (2%) Laryngitis (2%) Micturition disorder (4%) Urinary retention (7%) Abnormal vision (7%) Taste perversion (4%) Tinnitus (4%) Anisocoria (2%) Blepharospasm (2%) Eye allergy (2%) Disorder vestibular (2%) Muscle weakness (2%) Anemia (2%) |
250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Other AEs: Somnolence, Tremor... Other AEs: Somnolence (54%) Sources: Tremor (54%) Dizziness (54%) Headache (52%) Insomnia (25%) Influence on libido (21%) Nervousness (18%) Myoclonus (13%) Increased appetite (11%) Paresthesia (9%) Memory impairment (9%) Anxiety (9%) Twitching (7%) Concentration impaired (5%) Depression (5%) Hypertonia (4%) Sleep disorder (4%) Psychosomatic disease (3%) Yawning (3%) Confusion (3%) Speech disorder (3%) Dreaming abnormal (3%) Agitation (3%) Migraine (3%) Depersonalization (2%) Irritability (2%) Emotional lability (2%) Panic reaction (1%) Sweating increased (29%) Rash (8%) Pruritus (6%) Dermatitis (2%) Acne (2%) Dry skin (2%) Urticaria (1%) Dry mouth (84%) Constipation (47%) Nausea (33%) Dyspepsia (22%) Diarrhea (13%) Anorexia (12%) Abdominal pain (11%) Vomiting (7%) Flatulence (6%) Tooth disorder (5%) Gastrointestinal disorder (2%) Dysphagia (2%) Esophagitis (1%) Fatigue (39%) Weight increase (18%) Flushing (8%) Hot flushes (5%) Chest pain (4%) Fever (4%) Allergy (3%) Pain (3%) Localised edema (2%) Chills (2%) Postural hypotension (6%) Palpitation (4%) Tachycardia (4%) Pharyngitis (14%) Rhinitis (12%) Sinusitis (6%) Coughing (6%) Bronchospasm (2%) Epistaxis (2%) Micturition disorder (14%) Urinary tract infection (6%) Micturition frequency (5%) Urinary retention (2%) Dysuria (2%) Cystitis (2%) Abnormal vision (18%) Taste perversion (8%) Tinnitus (6%) Lacrimation abnormal (3%) Mydriasis (2%) Conjunctivitis (1%) Myalgia (13%) Back pain (6%) Arthralgia (3%) Muscle weakness (1%) Purpura (3%) Thirst (2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sweating | 13.4% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Nausea | 16.1% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Dizziness | 17.9% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Tremor | 22.3% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Somnolence | 24.1% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Constipation | 25% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Abdominal pain | 3.6% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Dry mouth | 42.9% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Insomnia | 8% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Asthenia | 9.8% | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, 35 n = 112 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: 35 Sex: M+F Population Size: 112 Sources: |
Insomnia | 11% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Abdominal pain | 13% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Dyspepsia | 13% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Aggressive reaction | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Anemia | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Anisocoria | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Anxiety | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Asthenia | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Blepharospasm | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Confusion | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Depersonalization | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Disorder vestibular | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Dyspnea | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Eructation | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Eye allergy | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Fever | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Halitosis | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Hot flushes | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Hypertonia | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Irritability | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Laryngitis | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Muscle weakness | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Myoclonus | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Panic reaction | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Paresis | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Paresthesia | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Pruritus | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Sinusitis | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Skin odor abnormal | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Syncope | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Tachycardia | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Ulcerative stomatitis | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Weight increase | 2% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Anorexia | 22% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Constipation | 22% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Headache | 28% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Tremor | 33% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Fatigue | 35% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Coughing | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Micturition disorder | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Nervousness | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Otitis media | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Pain | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Palpitation | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Postural hypotension | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Rash | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Taste perversion | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Tinnitus | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Twitching | 4% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Dizziness | 41% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Somnolence | 46% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Dry mouth | 63% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Abnormal vision | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Allergy | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Bronchospasm | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Chest pain | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Diarrhea | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Flushing | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Memory impairment | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Rhinitis | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Urinary retention | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Vomiting | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Weight decrease | 7% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Nausea | 9% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Sleep disorder | 9% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Sweating increased | 9% | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, Children and Adolescents n = 46 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: Children and Adolescents Sex: M+F Population Size: 46 Sources: |
Conjunctivitis | 1% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Esophagitis | 1% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Muscle weakness | 1% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Panic reaction | 1% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Urticaria | 1% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Abdominal pain | 11% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Increased appetite | 11% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Anorexia | 12% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Rhinitis | 12% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Diarrhea | 13% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Myalgia | 13% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Myoclonus | 13% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Micturition disorder | 14% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Pharyngitis | 14% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Abnormal vision | 18% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Nervousness | 18% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Weight increase | 18% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Acne | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Bronchospasm | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Chills | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Cystitis | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Depersonalization | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Dermatitis | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Dry skin | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Dysphagia | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Dysuria | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Emotional lability | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Epistaxis | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Gastrointestinal disorder | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Irritability | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Localised edema | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Mydriasis | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Thirst | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Urinary retention | 2% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Influence on libido | 21% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Dyspepsia | 22% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Insomnia | 25% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Sweating increased | 29% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Agitation | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Allergy | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Arthralgia | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Confusion | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Dreaming abnormal | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Lacrimation abnormal | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Migraine | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Pain | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Psychosomatic disease | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Purpura | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Speech disorder | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Yawning | 3% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Nausea | 33% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Fatigue | 39% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Chest pain | 4% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Fever | 4% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Hypertonia | 4% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Palpitation | 4% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Sleep disorder | 4% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Tachycardia | 4% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Constipation | 47% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Concentration impaired | 5% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Depression | 5% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Hot flushes | 5% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Micturition frequency | 5% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Tooth disorder | 5% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Headache | 52% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Dizziness | 54% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Somnolence | 54% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Tremor | 54% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Back pain | 6% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Coughing | 6% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Flatulence | 6% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Postural hypotension | 6% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Pruritus | 6% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Sinusitis | 6% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Tinnitus | 6% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Urinary tract infection | 6% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Twitching | 7% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Vomiting | 7% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Flushing | 8% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Rash | 8% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Taste perversion | 8% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Dry mouth | 84% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Anxiety | 9% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Memory impairment | 9% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Paresthesia | 9% | 250 mg 1 times / day multiple, oral (max) Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, adult n = 322 Health Status: unhealthy Condition: obsessive-compulsive disorder Age Group: adult Sex: M+F Population Size: 322 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | yes (pharmacogenomic study) Comment: administration of clomipramine to a CYP2C19 intermediate metabolizer resulted in elevated serum trough concentrations |
|||
yes | yes (pharmacogenomic study) Comment: administration of clomipramine to a CYP2D6 intermediate metabolizer resulted in elevated serum trough concentrations |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Depressive reactions in the course of clomipramine therapy used in the treatment of obsessional conditions. | 1975 |
|
Pharmacotherapy for severe aggression in a child with autism: "open label" evaluation of multiple medications on response frequency and intensity of behavioral intervention. | 2000 Sep-Dec |
|
Trichotillomania. Presentation, etiology, diagnosis and therapy. | 2001 |
|
Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats. | 2001 |
|
Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder. | 2001 |
|
Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. | 2001 |
|
Pharmacological characterization of the serotonin transporter in young and elderly subjects. | 2001 |
|
Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. | 2001 |
|
Tianeptine: a review of its use in depressive disorders. | 2001 |
|
Development of a depersonalization severity scale. | 2001 Apr |
|
Interaction of psychotropic drugs with monoamine oxidase in rat brain. | 2001 Aug |
|
Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone. | 2001 Aug |
|
Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. | 2001 Aug |
|
Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. | 2001 Aug |
|
S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. | 2001 Aug |
|
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. | 2001 Aug |
|
Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. | 2001 Dec 1 |
|
A review of the pharmacological and clinical profile of mirtazapine. | 2001 Fall |
|
Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. | 2001 Jul |
|
Severe, refractory hypotension during anesthesia in a patient on chronic clomipramine therapy. | 2001 Jul |
|
A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. | 2001 Jul |
|
The critical window of brain development from susceptive to insusceptive. Effects of clomipramine neonatal treatment on sexual behavior. | 2001 Jul 23 |
|
[Tricyclic antidepressants dosage and depressed elderly inpatients: a retrospective pharmaco-epidemiologic study]. | 2001 Jul-Aug |
|
Digitalis intoxication misdiagnosed as depression--revisited. | 2001 Jul-Aug |
|
Neurobiology and clinical pharmacology of obsessive-compulsive disorder. | 2001 Jul-Aug |
|
Clomipramine--beyond separation anxiety. | 2001 Jul-Aug |
|
Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines. | 2001 Jun |
|
Pharmacological manipulations of the extinction process of fear-induced ultrasonic vocalization in rats. | 2001 Jun |
|
Diurnal profile of melatonin concentrations in patients with major depression: relationship to the clinical manifestation and antidepressant treatment. | 2001 Jun |
|
[Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature]. | 2001 May-Jun |
|
[Narcolepsy in a prepubertal boy]. | 2001 Nov |
|
Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. | 2001 Nov |
|
Adults with early-onset obsessive-compulsive disorder. | 2001 Nov |
|
Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. | 2001 Oct |
|
Clinical predictors of drug response in obsessive-compulsive disorder. | 2001 Oct |
|
Clomipramine discontinuation-emergent dystonia. | 2001 Oct |
|
Obsessive-compulsive symptoms during treatment with clozapine in a patient with schizophrenia. | 2001 Oct |
|
Ping-pong gaze in combined intoxication with tranylcypromine, thioridazine, and clomipramine. | 2001 Oct-Dec |
|
Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. | 2001 Sep |
|
Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. | 2001 Sep |
|
[Chronic discomfort with dentures - successful treatment with clomipramine]. | 2001 Sep |
|
Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors? | 2001 Sep |
|
Comment: serotonin syndrome and 5-HT2A antagonism. | 2001 Sep |
|
Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake. | 2001 Sep |
|
Repeated but not acute clomipramine decreases the effect of N-methyl-D-aspartate receptor activation on serotonergic transmission between the raphe nuclei and frontal cortex. | 2001 Sep |
|
HPLC of basic drugs on microparticulate strong cation-exchange materials - a review. | 2001 Sep 15 |
|
Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors. | 2001 Sep 15 |
|
High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. | 2001 Sep 25 |
|
Effects of clomipramine on Trypanosoma cruzi infection in mice. | 2001 Sep-Oct |
|
Diurnal profile of melatonin secretion in the acute phase of major depression and in remission. | 2001 Sep-Oct |
Sample Use Guides
Adults: Treatment should be initiated at a dosage of 25 mg daily and gradually increased, as tolerated, to approximately 100 mg during the first 2 weeks. During initial titration, the drug should be given in divided doses with meals to reduce gastrointestinal side effects. Thereafter, the dosage may be increased gradually over the next several weeks, up to a maximum of 250 mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1161997
The effect of clomipramine, at concentrations of 10(-7)M to 10(-4)M, was studied in vitro on the uptake of 5-hydroxytryptamine and dopamine uptake in human platelet-rich plasma.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 12:54:46 UTC 2021
by
admin
on
Sat Jun 26 12:54:46 UTC 2021
|
Record UNII |
NUV44L116D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ESSENTIAL MEDICINES LIST |
24.4
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
||
|
NDF-RT |
N0000175752
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
||
|
WHO-ATC |
N06AA04
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
||
|
CFR |
21 CFR 520.455
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
||
|
NCI_THESAURUS |
C94727
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
CLOMICALM (AUTHORISED)
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
||
|
WHO-VATC |
QN06AA04
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
||
|
LIVERTOX |
223
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C61608
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
2597
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | RxNorm | ||
|
303-49-1
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
SUB06725MIG
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
Clomipramine
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
CHEMBL415
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
701
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
2238
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
M3648
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | Merck Index | ||
|
CLOMIPRAMINE
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
D002997
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
DB01242
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
7746
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
206-144-2
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
2801
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
2398
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
NUV44L116D
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY | |||
|
303-49-1
Created by
admin on Sat Jun 26 12:54:47 UTC 2021 , Edited by admin on Sat Jun 26 12:54:47 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Pharmacological action: Tricyclic antidepressant drug (TCA)
|
||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Metabolizing reaction by CYP2D6: 2- and 8-Hydroxylation
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||